Akelos Inc.'s SAB Member Co-Authors Paper Validating HCN1 as a Therapeutic Target for the Treatment of Peripheral Neuropathic Pain

NEW YORK - February 5, 2021 - (Newswire.com)

Dr. Peter Goldstein, scientific co-founder of Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain, has just co-authored a review article in the peer-reviewed journal Current Neuropharmacology (doi: 10.2174/1570159X19666210119153047. Online ahead of print) that highlights the rationale for targeting HCN1 in sensory neurons for the treatment of peripheral neuropathic pain.

Dr. Goldstein, Professor of Anesthesiology, Professor of Anesthesiology in Neuroscience in the Feil Family Brain and Mind Research Institute, and Associate Professor of Medical Ethics in Medicine at Weill Cornell Medicine (New York, NY) and senior author of the paper, observes: "Novel antihyperalgesics are urgently needed to provide pain relief and minimize disability without the attendant risks of existing therapies. A promising strategy for the development of novel antihyperalgesics is to target ion channels involved in nociception, including the "low-hanging" targets that control peripheral neuronal hyperexcitability. Our work, and that of others, clearly demonstrates that HCN1 channels are indeed such "low-hanging'' fruit."

Akelos Inc. is in a research collaboration with Weill Cornell Medicine to develop and commercialize a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain. Dr. Goldstein is a scientific advisory board member of Akelos, Inc.

For more information, please contact:

Akelos Inc.
Dr. Steven Fox, CEO
212-953-1544
drstevefox@akelosinc.com

Akelos Inc. Forward-Looking Statement: This press release contains forward-looking statements. These forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Akelos, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. These statements include, among others, those related to: the results of research and development activities, uncertainties relating to preclinical and clinical testing, the cost, timing and outcome of the regulatory development and approval process, our budgets, expenditures and financing plans, our need for substantial additional funds, patent and intellectual property matters, our dependence on third parties, including contract research and contract clinical trial organizations; and market opportunity and competition.

The information contained in this press release is believed to be current as of the date of original issue. Akelos, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Press Release Service by Newswire.com

Original Source: Akelos Inc.'s SAB Member Co-Authors Paper Validating HCN1 as a Therapeutic Target for the Treatment of Peripheral Neuropathic Pain